SARS-CoV-2

Online Platform Launched to Help COVID-19 Test Manufacturers Prepare for New Variants

The NIH-funded ROSALIND Diagnostic Monitoring platform has just been launched to provide test developers and regulators with rapid and regular updates about SARS-CoV-2 variants of concern and their distribution and assess the impact of these variants on available diagnostic test performance.
Tempus has raised an additional $80 million in financing

With $80M in New Financing, Tempus Plans Further Platform Growth

Company has now raised $210M in three years with plans to build the world's largest library of clinical and molecular data for clinical use
Genetic test results

Advanced AI Technology for Clinical Genomic Support Across All Stages of Life

Adoption of clinical genomics applications has been driven by increasingly scalable genomic technologies. Higher-throughput approaches to genetic testing have resulted in increased diagnostic yields and discovery coupled with advances in bioinformatic analysis tools.
CancerLinQ says its new partnership with the Oncology Nursing Society (ONS) is intended to draw upon the Society’s expertise and thought leadership.(Source: iStock/KatarzynaBialasiewicz)

CancerLinQ Expands Alliance with Oncology Nursing Society

New partnership comes two months after CancerLinQ and ONS launch CancerLinQ Ambassadors Program, a national practice engagement initiative.
Source: KATERYNA KON/SCIENCE PHOTO LIBRARY

Geisinger Gets $3.1M NIH Grant to Study Sudden Cardiac Death

Geisinger researchers will tap data of more than 90,000 whole-exome sequences from MyCode of patients with ARVC-related genetic findings
OnRamp Bioinformatics has integrated its flagship ROSALIND genomic data analysis software (pictured) with Active Motif’s kits and antibodies in an epigenetics collaboration aimed at improving the accuracy of data analysis for chromatin immunoprecipitation (ChIP) sequencing experiments. [OnRamp Bioinformatics]

OnRamp Bioinformatics, Active Motif Partner on ChIP-seq Data Analysis

Collaboration aimed at improving the accuracy of data analysis for chromatin immunoprecipitation (ChIP) sequencing experiments.
Merck KGaA and software company Palantir Technologies are forming a joint venture to develop a collaborative technology platform to advance cancer research. [© Robert Mizerek/Fotolia]

Merck KGaA, Palantir Form Joint Venture to Develop Cancer Data Platform

Syntropy’s platform will be designed to facilitate secure, transparent sharing of data between participating researchers and institutions.
DNA Sequence

EMBL-EBI Launches Free Genetic Disease Diagnostic Software

Researchers at the University of Edinburgh and the European Bioinformatics Institute at the European Molecular Biology Laboratory (EMBL-EBI) have introduced a new diagnostic genome-wide...

Method Developed to Increase Equity in Genomic Databases

Known as Summix, the method adjusts information to match the ancestry of a person or sample of people with the goal of making large genetic databases more useful for people of traditionally underrepresented ancestries.
Black doctor using digital display

The Age of Analytics: Sequencing’s New Frontier Is Clinical Interpretation

David FitzPatrick’s typical patient is a toddler with global developmental delay who is small for her age, has epilepsy, and cannot speak or understand...

Featured